SAN DIEGO, July 5, 2018 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabiscompany in the United States, today announced that both the Company and its subsidiaries Kannaway® and HempMeds® Mexico have booked their largest-ever (unaudited) sales in their
"We are pleased to announce June of 2018 was the largest month in the history of our Company," said Medical Marijuana, Inc. CEO Dr. Stuart Titus. "We're looking forward to our expansion into Canada's emerging cannabis market and to building upon our success in July."
Medical Marijuana, Inc. and its subsidiaries experienced many accomplishments in June 2018 including a new partnership with Peak Health to distribute the first-ever, and only, hops (Kriya brand Humulus)-derived cannabidiol (CBD) product, ImmunAg™. The Company also signed a non-binding Letter of Intent (LOI) with Salvation Botanicals to bring its internationally recognized cannabis expertise to the Canadian cannabis market.
"This achievement proves Medical Marijuana, Inc. and its subsidiaries will continue to be leaders in the industry," said Medical Marijuana, Inc. COO Blake Schroeder. "This month was historic for the Company and we believe 2018 will continue to be a banner year for the Company."
Milestones also include Medical Marijuana, Inc. subsidiary HempMeds® announcing the historic authorization of its Real Scientific Hemp Oil-X™ (RSHO-X™) CBD hemp oil product for import into Argentina, as well as obtaining positive news coverage in several national and international news outlets including The History Channel, Chicago Tribune, Benzinga, Shape Magazine, Medium and Vice.
About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.'s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.'s shop.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
CONTACT:Public Relations Contact:Andrew HardChief Executive Officer CMW MediaP. 858-264-6600 firstname.lastname@example.org www.cmwmedia.com
View original content:http://www.prnewswire.com/news-releases/medical-marijuana-inc-and-subsidiaries-announce-june-2018-as-the-largest-sales-month-in-company-history-300676217.html
SOURCE Medical Marijuana, Inc.
Subscribe to our Free Newsletters!
Take the quiz on Rabies and test your knowledge about this infection that can affect the brain ...
Pneumonitis usually refers to inflammation of lung tissue due to various non-infective causes such ...
Fremanezumab-vfrm is used as a preventive treatment for a migraine headache in adult patients. It ...View All